Effect of daily chlorhexidine bathing on hospital-acquired infection

New England Journal of Medicine

Volumn 368, Issue 6, 2013, Pages 533-542

  Climo, Michael W ^a,b   Yokoe, Deborah S ^c   Warren, David K ^d   Perl, Trish M ^e   Bolon, Maureen ^f   Herwaldt, Loreen A ^h   Weinstein, Robert A ^g   Sepkowitz, Kent A ⁱ   Jernigan, John A ^j   Sanogo, Kakotan ^b   Wong, Edward S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g Cook County Health and Hospitals System ^*  (United States)

^h UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE GLUCONATE;

ACINETOBACTER; ARTICLE; BACTERIAL COLONIZATION; BLOODSTREAM INFECTION; BONE MARROW TRANSPLANTATION; CANDIDA; CATHETER INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISINFECTION; ENTEROBACTER; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION RATE; INTENSIVE CARE UNIT; KLEBSIELLA; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS; RANDOMIZED CONTROLLED TRIAL; SERRATIA; SKIN MANIFESTATION; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 84873512888     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1113849     Document Type: Article

References (35)

1. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public health threat. Lancet 2006;368:874-85.
2. Bouchillon SK, Johnson BM, Hoban DJ, et al. Determining incidence of extended spectrum β-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001-2002. Int J Antimicrob Agents 2004;24:119-24.
3. Kreman T, Hu J, Pottinger J, Herwaldt LA. Survey of long-term-care facilities in Iowa for policies and practices regarding residents with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2005;26:811-5.
4. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-8.
5. Furuno JP, Hebden JN, Standiford HC, et al. Prevalence of methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii in a long-term acute care facility. Am J Infect Control 2008;36:468-71.
6. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for Isolation Precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007;35:Suppl 2:S65-S164.
7. Warren DK, Quadir WW, Hollenbeak CS, Elward AM, Cox MJ, Fraser VJ. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 2006;34:2084-9.
8. Roberts RR, Scott RD II, Hota B, et al. Costs attributable to healthcare-acquired infection in hospitalized adults and a comparison of economic methods. Med Care 2010;48:1026-35.
9. Stone PW, Glied SA, McNair PD, et al. CMS changes in reimbursement for HAIs: setting a research agenda. Med Care 2010;48:433-9.
10. Sipkoff M. Hospitals asked to account for errors on their watch: CMS and states may stop paying for specific hospital-acquired conditions: will health plans follow suit? Manag Care 2007;16:30, 35-7.
11. Warren DK, Cosgrove SE, Diekema DJ, et al. A multicenter intervention to prevent catheter-associated bloodstream infections. Infect Control Hosp Epidemiol 2006;27:662-9.
12. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32. [Erratum, N Engl J Med 2007;356:2660.]
13. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ 2010;340:c309.
14. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA. Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 2006;166:306-12.
15. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 2007;167:2073-9.
16. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009;37:1858-65.
17. Performance Standards for Antimicrobial Susceptibility Testing: Fourteenth Informational Supplement (M100-S14). Wayne, PA: National Committee for Clinical Laboratory Standards, 2004.
18. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-32. [Erratum, Am J Infect Control 2008;36:655.]
19. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009;30:959-63.
20. Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009;30:1031-5.
21. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999;12:147-79. [Erratum, Clin Microbiol Rev 2001;14:227.]
22. Lockhart SR, Wagner D, Iqbal N, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol 2011;49:2404-10.
23. Sijbesma T, Röckmann H, van der Weegen W. Severe anaphylactic reaction to chlorhexidine during total hip arthroplasty surgery: a case report. Hip Int 2011;21:630-2.
24. Bringué Espuny X, Soria X, Solé E, et al. Chlorhexidine-methanol burns in two extreme preterm newborns. Pediatr Dermatol 2010;27:676-8.
25. Cheng CE, Kroshinsky D. Iatrogenic skin injury in hospitalized patients. Clin Dermatol 2011;29:622-32.
26. Liippo J, Kousa P, Lammintausta K. The relevance of chlorhexidine contact allergy. Contact Dermat 2011;64:229-34.
27. McGann P, Kwak YI, Summers A, Cummings JF, Waterman PE, Lesho EP. Detection of qacA/B in clinical isolates of methicillin-resistant Staphylococcus aureus from a regional healthcare network in the eastern United States. Infect Control Hosp Epidemiol 2011;32:1116-9.
28. Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008;61:78-84.
29. Sheng WH, Wang JT, Lauderdale TL, Weng CM, Chen D, Chang SC. Epidemiology and susceptibilities of methicillinresistant Staphylococcus aureus in Taiwan: emphasis on chlorhexidine susceptibility. Diagn Microbiol Infect Dis 2009;63:309-13.
30. Alam MM, Kobayashi N, Uehara N, Watanabe N. Analysis on distribution and genomic diversity of high-level antiseptic resistance genes qacA and qacB in human clinical isolates of Staphylococcus aureus. Microb Drug Resist 2003;9:109-21.
31. Longtin J, Seah C, Siebert K, et al. Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009. Antimicrob Agents Chemother 2011;55:2999-3001.
32. Vali L, Davies SE, Lai LL, Dave J, Amyes SG. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother 2008;61:524-32.
33. Noguchi N, Nakaminami H, Nishijima S, Kurokawa I, So H, Sasatsu M. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol 2006;44:2119-25.
34. Lee AS, Macedo-Vinas M, François P, et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011;52:1422-30.
35. Weber DJ, Rutala WA, Sickbert-Bennett EE. Outbreaks associated with contaminated antiseptics and disinfectants. Antimicrob Agents Chemother 2007;51:4217-24.